Homologation (recognition of equivalence) is a useful tool for simplifying administrative processes that are repeated in different countries. Nevertheless, it is not an end in itself.
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains.
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions.
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.
A recent US district court ruling could significantly affect companies that patent genes and threaten the health of an entire industry. LSIPR investigates.
The European Court of Justice is faced with a crucial decision on stem cell research. Justin Turner QC explains.
Following the implementation of EU Directive 2004/48/EC on the enforcement of IP rights under French patent law in 2007 and the publication of the corresponding implementing rules in 2008, the criteria adopted by the French courts to grant preliminary injunctions have also changed.
A growing number of biotechnology inventions relate to peptides, oligonucleotides and other small molecules that could be used in therapeutic applications. Caroline Pallard explains the challenges of patenting such inventions.
Two pharmaceutical cases highlight recent developments in Canadian patent law relating to duty of candour during patent prosecution and patent claim construction, says Katie Wang.
There is a contradiction at the heart of product definition in Swedish supplementary protection certificates, says Hampus Rystedt.